FLR Fluor (FLR) Q1 FY26 earnings call
Fluor delivered strong Q1 operating cash flow and continued its capital return program, driven by an asset-light strategy. The company reported significant growth in its prospect pipeline and maintained project selectivity, aiming for higher-margin new awards. While navigating specific project charges and geopolitical uncertainties, Fluor remains focused on converting front-end awards into full EPC releases and exploring strategic M&A opportunities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
FLR operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Backlog | $25.7BOur backlog improved slightly from year-end to $25.7 billion and reflects an additional $1.1 billion in positive project adjustments on current work.Source: earnings call transcript | $26.9BEnding backlog was $26.9 billion and reflects our sizable Q2 awards and the removal of just over $650 million of backlog related to our now former JV in Mexico.Source: earnings call transcript | +4.7% |
| Orders Urban Solutions | $2.1BNew awards for the quarter were $2.1 billion compared to $5.3 billion a year ago when we received a multibillion-dollar award for a life sciences project.Source: earnings call transcript | $3.2BFor the quarter, Urban Solutions new awards were $3.2 billion and include construction management for our copper mine in Chile, a feasibility study for Anglo's fertilizer project in the UK and expand its scope for a fertilizer project in Canada, additional scope on the life sciences project in the US and an infrastructure project in Europe.Source: earnings call transcript | +52.4% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.